SCHEMBL712709

SCHEMBL712709

Oc1ccc(/C=C/c2cnc3ccccc3n2)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 8/20 0.64
NPC1 O15118 6/20 0.64
KMT2A Q03164 5/20 0.64
MEN1 O00255 4/20 0.64
LMNA P02545 4/20 0.64
ALDH1A1 P00352 4/20 0.64
KDM4E B2RXH2 4/20 0.64
SMN1; SMN2 Q16637 4/20 0.64
MAPT P10636 3/20 0.64
L3MBTL1 Q9Y468 1/20 0.64
PAX8 Q06710 1/20 0.56
BCHE P06276 1/20 0.51
HPGD P15428 1/20 0.49
CASP3 P42574 1/20 0.49
HTT P42858 1/20 0.49
SENP7 Q9BQF6 1/20 0.49
CD74 P04233 1/20 0.45
MIF P14174 1/20 0.45
PKM P14618 1/20 0.45
GAA P10253 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL712710 1.00 RAB9A (0.64) RAB9ANPC1KMT2AMEN1LMNA
SCHEMBL12923109 0.91 PAX8 (0.63) RAB9ANPC1KMT2AMEN1LMNA
SCHEMBL711461 0.86 KDM4E (0.59) RAB9ANPC1KMT2AMEN1LMNA
SCHEMBL711460 0.86 KDM4E (0.59) RAB9ANPC1KMT2AMEN1LMNA
SCHEMBL710216 0.83 PAX8 (0.56) RAB9ANPC1KMT2AMEN1LMNA
SCHEMBL708682 0.83 PAX8 (0.56) RAB9ANPC1KMT2AMEN1LMNA
SCHEMBL708683 0.83 PAX8 (0.56) RAB9ANPC1KMT2AMEN1LMNA
SCHEMBL708372 0.83 PAX8 (0.56) RAB9ANPC1KMT2AMEN1LMNA
SCHEMBL714075 0.83 PAX8 (0.56) RAB9ANPC1KMT2AMEN1LMNA
SCHEMBL714074 0.83 PAX8 (0.56) RAB9ANPC1KMT2AMEN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8124625-B2 enhancing the expression of apoAI; prevention or therapy of dislipidemia SHIONOGI & CO., LTD. (JP) 2012-02-28 US disclosed
US-8053445-B2 Utilities of olefin derivatives SHIONOGI & CO., LTD. (JP) 2011-11-08 US disclosed
US-20090036457-A1 Utilities of olefin derivatives YAMAMORI TERUO 2009-02-05 US disclosed
US-20040242615-A1 Utilities of olefin derivatives SHIONOGI & CO., LTD. (JP) 2004-12-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040242615-A1 Utilities of olefin derivatives APOL1, NR1H2, APOB RAB9A 4723/4885NPC1 19/4885KMT2A 3382/4885
US-20090036457-A1 Utilities of olefin derivatives APOL1, APOB, NR1H2 RAB9A 4606/4885NPC1 48/4885KMT2A 3744/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.